In the latest trading session,, 1.12 million Astrazeneca plc ADR (NASDAQ:AZN) shares changed hands as the company’s beta touched 0.39. With the company’s most recent per share price at $73.89 changing hands around $0.06 or 0.07% at last look, the market valuation stands at $229.14B. AZN’s current price is a discount, trading about -18.66% off its 52-week high of $87.68. The share price had its 52-week low at $61.24, which suggests the last value was 17.12% up since then.
Analysts gave the Astrazeneca plc ADR (AZN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.37. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AZN as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. Astrazeneca plc ADR’s EPS for the current quarter is expected to be 1.14.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Instantly AZN is in green as seen in intraday trades today. With action 1.21%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 12.77%, with the 5-day performance at 1.21% in the green. However, in the 30-day time frame, Astrazeneca plc ADR (NASDAQ:AZN) is 7.16% up.
The consensus price target for the stock as assigned by Wall Street analysts is 85, meaning bulls need an upside of 13.07% from its recent market value. According to analyst projections, AZN’s forecast low is 79 with 88 as the target high. To hit the forecast high, the stock’s price needs a -19.1% plunge from its current level, while the stock would need to soar -6.92% for it to hit the projected low.
Astrazeneca plc ADR (AZN) estimates and forecasts
Year-over-year growth is forecast to reach 6.95% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 14.08B. 8 analysts are of the opinion that Astrazeneca plc ADR’s revenue for the current quarter will be 14.57B. The company’s revenue for the corresponding quarters a year ago was 12.94B and 13.56B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 8.83%. The estimates for the next quarter sales put growth at 7.42%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.63%. The 2025 estimates are for Astrazeneca plc ADR earnings to increase by 10.20%, but the outlook for the next 5-year period is at 11.28% per year.
AZN Dividends
Astrazeneca plc ADR is expected to release its next quarterly earnings report in July. The 2.10% annual yield figure for the share gives it an annual dividend of 1.55. It is important to note, however, that the 2.10% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
PRIMECAP MANAGEMENT CO/CA/ holds the second largest percentage of outstanding shares, with 2.7411% or 42.6 million shares worth $3.32 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund and WASHINGTON MUTUAL INVESTORS FUND . With 25.51 shares estimated at $1.88 billion under it, the former controlled 0.97% of total outstanding shares. On the other hand, WASHINGTON MUTUAL INVESTORS FUND held about 0.76% of the shares, roughly 20.06 shares worth around $1.48 billion.
